9-Methyl-β-Carboline for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

9-Methyl-β-Carboline for Health & Longevity

Created on 06/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

An experimental molecule that, unlike most of its chemical family, appears to support rather than harm dopamine-producing brain cells. In animals it improved learning and protected dopamine neurons. All evidence is from cells and rodents; no human studies or safety testing exist. Concerns: DNA damage under ultraviolet light and interactions with common drugs and foods. (Full Review)

Protocol

Typical reported dose
10–25 mg/day
Some users range to 30 mg; from anecdote and rough rodent extrapolation, not human dose-finding.
Best time of day
Morning
Morning dosing is usual practice to avoid insomnia from stimulation and possible sleep disruption.
Single vs. split dosing
Once-daily single dose
Justified by the presumed long half-life and the goal of steady exposure rather than acute peaks.
Time to effect
Cognitive benefit
~1–2 weeks
Rodent cognitive benefit required 10 days of dosing and was absent at 5 days; users run multi-week blocks.
Acute effect
None expected
Users expecting an immediate stimulant-like effect are often disappointed; benefit needs sustained dosing.
Expected half-life
~15–24 hours
Unverified community extrapolation; human half-life has not been measured. Implies once-daily dosing.

Benefits

Contraindications
  • MAO inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide)
  • Pregnancy or breastfeeding
  • Bipolar disorder or psychotic disorders
  • Uncontrolled hypertension
  • Significant photosensitivity or other photosensitizing drugs
    •
Key Interactions
  • Serotonergic drugs (SSRIs sertraline, fluoxetine; SNRIs venlafaxine; triptans; tramadol)
  • Dopaminergic drugs and stimulants (levodopa, amphetamines, methylphenidate, bupropion)
  • OTC sympathomimetics and cold remedies (pseudoephedrine, phenylephrine, dextromethorphan)
  • Tyramine-rich foods (aged cheeses, cured meats, fermented products)
  • Additive dopaminergic/monoamine supplements (L-tyrosine, Mucuna pruriens, harmine/harmaline, St. John's Wort)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Phototoxicity and DNA photodamage
    •
  • Speculative: Dopaminergic neurotoxicity at high or chronic doses; serotonin excess from MAO-A inhibition; common subjective side effects (nausea, headache, overstimulation); unknown long-term and reproductive safety
    •

Monitoring

Marker Target Why
Blood pressure ~110–125 / 70–80 mmHg Detects pressor effect from MAO inhibition or stimulation
Resting heart rate 55–70 bpm Detects sympathetic overstimulation
Liver enzymes (ALT, AST) ALT ~10–26 U/L; AST ~15–26 U/L Screens for hepatic stress given no organ-safety data
Fasting glucose 75–90 mg/dL General metabolic safety reference during any new compound

Cadence: Blood pressure and heart rate in the first week and at any dose increase; reassess mood and sleep at ~2 and 4 weeks; liver-function testing at baseline and again at ~8–12 weeks for use beyond a few weeks.

Qualitative Assessment

  • Subjective focus, motivation, and mental clarity (the intended cognitive effects)
  • Mood stability versus irritability, anxiety, or overstimulation
  • Sleep onset and quality
  • Any nausea or headache, especially after dosing or dose increases
  • Skin sensitivity to sunlight
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.